Drugs / amdoxovir
amdoxovir
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00432016 | Feb → May 2007 | HIV infectious disease | RFS Pharma, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT00031044 | ? → Nov 2004 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01738555 | Apr 2013 → Aug 2014 | HIV infectious disease | RFS Pharma, LLC | Withdrawn | No outcome recorded |
| Phase 2 | NCT01737359 | Dec 2012 → Feb 2013 | HIV infectious disease | RFS Pharma, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00038272 | ? → Apr 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | amdoxovir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01737359 ↗ |
| Known as | 2,6-diaminopurine dioxolane | “Amdoxovir (2,6-diaminopurine dioxolane; DAPD) is a nucleoside reverse transcriptase inhibitor (NRTI) of human immunodeficiency virus-1 (HIV-1) with activity against wild-type...” PMID 16964830 ↗ 2006 |
| Known as | AMDX | “The purpose of this study is to determine the short term safety, tolerance, and antiviral effect of zidovudine (AZT) and amdoxovir (AMDX, DAPD) in combination, and whether the...” NCT00432016 ↗ |
| Known as | DAPD | “The purpose of this study is to determine the short term safety, tolerance, and antiviral effect of zidovudine (AZT) and amdoxovir (AMDX, DAPD) in combination, and whether the...” NCT00432016 ↗1“Amdoxovir (2,6-diaminopurine dioxolane; DAPD) is a nucleoside reverse transcriptase inhibitor (NRTI) of human immunodeficiency virus-1 (HIV-1) with activity against wild-type...” PMID 16964830 ↗ 2006 |
| Action | Inhibit | “is a nucleoside reverse transcriptase inhibitor” PMID 16964830 ↗ 2006 |
| Modality | Small molecule | “nucleoside reverse transcriptase inhibitor (NRTI)” PMID 16964830 ↗ 2006 |
| Route | Oral | “DAPD (300 mg orally, twice daily)” PMID 16964830 ↗ 2006 |